Advisory Research’s Ligand Pharmaceuticals LGND Stock Holding History

Advisory Research’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,926	Closed	-$502K	–	365
2018 Q4	$502K	Sell	5,926 -2,499	-30%	-$266K	0.01%	294
2018 Q3	$1.44M	Sell	8,425 -6,295	-43%	-$949K	0.02%	230
2018 Q2	$1.9M	Sell	14,720 -42	-0.3%	-$4.69K	0.03%	217
2018 Q1	$1.52M	Buy	+14,762	New	+$1.46M	0.03%	235

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Advisory Research's LGND Position: Q1 2019 in Review

Advisory Research sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 5,926 shares — an estimated $502K sold.

Advisory Research first reported a position in LGND in Q1 2018 and held it in 4 quarters. The position peaked at $1.9M in Q2 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

Advisory Research reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Advisory Research sold 5,926 Ligand Pharmaceuticals shares in Q1 2019, an estimated $502K.
Advisory Research first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 4 quarters.
Advisory Research's Ligand Pharmaceuticals position peaked at $1.9M in Q2 2018.
330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Advisory Research's 13F filing for Q1 2019, filed 15 May 2019.